Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. reports clinical-stage vaccine developments focused on bacterial diseases, led by pneumococcal conjugate vaccine candidates in its PCV franchise. Recurring updates cover VAX-31 clinical studies in adult and infant populations, earlier PCV candidates including VAX-24 and VAX-XL, and pipeline programs such as VAX-A1 for Group A Strep and VAX-GI for Shigella.
Company news also addresses the XpressCF cell-free protein synthesis platform licensed from Sutro Biopharma, manufacturing and commercial-readiness activities, equity financings, quarterly financial results, and healthcare conference participation. These releases tie Vaxcyte’s vaccine engineering platform to clinical progress, supply-chain development, and capital resources supporting its pipeline.
Vaxcyte (Nasdaq: PCVX) reported Q1 2026 results and a business update. As of March 31, 2026, cash, cash equivalents and investments totaled $2.74 billion. Enrollment is complete for three VAX-31 adult Phase 3 OPUS trials (6,191 adults dosed). OPUS-1 topline data expected Q4 2026; OPUS-2 and OPUS-3 results expected H1 2027. Infant Phase 2 enrollment completed (900 infants); infant readouts expected by end of H1 2027. Company plans to start a Phase 1 adult study for VAX-A1 in mid-2026. Q1 R&D expense was $312.8 million and net loss was $320.6 million.
Vaxcyte (Nasdaq: PCVX) said management will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast will be available on the company investor site, with a replay for ~30 days.
Vaxcyte (Nasdaq: PCVX) completed enrollment in its VAX-31 Phase 3 program: OPUS-1 (~4,000 participants) and OPUS-2 (~1,300 participants). OPUS-3 enrollment is ongoing. The program was designed with FDA alignment to support a planned BLA. Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 results expected H1 2027.
VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease and pneumonia in adults.
Vaxcyte (Nasdaq: PCVX) announced publication of positive Phase 1/2 adult data for VAX-31 in The Lancet Infectious Diseases on March 18, 2026. The VAX-31 High Dose met or exceeded OPA non-inferiority for 20 shared serotypes and met superiority for 11 incremental serotypes versus PCV20.
VAX-31 showed robust OPA and IgG responses across all 31 serotypes, a safety profile similar to Prevnar 20, and is being evaluated in the OPUS Phase 3 adult program with topline data expected in Q4 2026.
Vaxcyte (Nasdaq: PCVX) reported fourth-quarter and full-year 2025 results and provided a business update on Feb 24, 2026. The company has ~$2.44 billion in cash and investments at year-end, completed a $632.5M public offering in Feb 2026, advanced a three-trial VAX-31 Phase 3 adult program, completed VAX-31 infant enrollment (900 infants), and finished a Lonza manufacturing buildout to support potential commercialization.
Vaxcyte (Nasdaq: PCVX) dosed the first participants in OPUS-3, a Phase 3 trial of its 31-valent pneumococcal conjugate vaccine, VAX-31, in adults previously vaccinated with lower-valency pneumococcal vaccines. The adult Phase 3 program totals ~6,000 participants, ~3,400 expected to receive VAX-31, and is aligned with the FDA to support a planned BLA.
Topline timing: OPUS-1 topline expected in Q4 2026; OPUS-2 and OPUS-3 topline data expected in H1 2027. VAX-31 is designed to cover ~95% of IPD and ~88% of pneumococcal pneumonia in U.S. adults 50+, with incremental coverage vs. standard-of-care of 14–34% (IPD) and 19–31% (pneumonia).
Vaxcyte (Nasdaq: PCVX) will report Q4 and full-year 2025 financial results and provide a business update on February 24, 2026 after market close. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT.
A live webcast will be available on the company website and a replay will be accessible for about 30 days.
Vaxcyte (Nasdaq: PCVX) management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
A live webcast will be available via the company Investor site and a replay will be accessible for approximately 30 days after the conference.
Vaxcyte (Nasdaq: PCVX) closed an underwritten public offering of 12,650,000 shares at $50.00 per share, including full exercise of a 1,650,000-share underwriter option. The aggregate gross proceeds were $632.5 million, before underwriting discounts, commissions, and offering expenses. A shelf registration was effective May 24, 2024.
Vaxcyte (Nasdaq: PCVX) priced an underwritten public offering of 11,000,000 common shares at $50.00 per share, for aggregate gross proceeds of $550 million before fees. The company granted a 30-day option for up to 1,650,000 additional shares.
The offering is expected to close on February 2, 2026, subject to customary closing conditions, and a final prospectus will be filed with the SEC.